GlassScriptPhysician profile
Richard Y Kim
NPI 1902890981
$4,204.57
in general payments reported to CMS, 2019-2025
34 companies · $1,703 in 2025
The $1,703 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $95.92 · 2020: $50.49 · 2021: $14.83 · 2022: $19.78 · 2023: $860 · 2024: $1,460 · 2025: $1,703.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,010 · Education: $13.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,009.66 |
| Education | $13.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,048.24 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Abbvie INC. | $610.00 | 2023-2025 | |
| Amgen INC. | $409.92 | 2023-2025 | Repatha, Otezla, Repatha |
| Pfizer INC. | $322.21 | 2023-2025 | |
| Lilly USA, LLC | $232.98 | 2023-2025 | Mounjaro, Zepbound, Kisunla |
| Astrazeneca Pharmaceuticals LP | $200.75 | 2023-2025 | Farxiga, Breztri, Airsupra |
| Supernus Pharmaceuticals, INC. | $170.39 | 2019-2025 | Qelbree, Qelbree |
| Otsuka America Pharmaceutical, INC. | $130.82 | 2023-2025 | Rexulti |
| Exact Sciences Corporation | $118.21 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astellas Pharma US INC | $90.86 | 2024-2025 | Veozah |
| Abbott Laboratories | $74.04 | 2022-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Daiichi Sankyo INC. | $71.14 | 2023-2025 | Injectafer |
| Glaxosmithkline, LLC. | $60.62 | 2019-2025 | Arexvy, Shingrix |
| Medtronic, INC. | $60.44 | 2025 | Symplicity G3 |
| Bayer Healthcare Pharmaceuticals INC. | $58.25 | 2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $50.89 | 2025 | Fanapt |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $48.82 | 2025 | Caplyta |
| Merck Sharp & Dohme LLC | $45.78 | 2024 | Gardasil, Gardasil 9, Capvaxive |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.65 | 2023 | Jardiance, Tradjenta |
| Lundbeck LLC | $38.47 | 2025 | Rexulti |
| Globus Medical, INC. | $33.71 | 2025 | Senza |
| Recor Medical INC | $32.64 | 2025 | Paradise Ultrasound Renal Denervation System |
| Amarin Pharma, INC. | $30.71 | 2020-2021 | |
| Xeris Pharmaceuticals, INC. | $24.28 | 2024 | Recorlev |
| Genentech USA, INC. | $23.17 | 2019 | |
| Horizon Therapeutics Plc | $22.76 | 2023 | Tepezza |
| Sumitomo Pharma America, INC. | $22.49 | 2025 | Gemtesa |
| Dynavax Technologies Corporation | $22.41 | 2023 | Heplisav-B |
| Agios Pharmaceuticals, INC. | $20.05 | 2025 | Pyrukynd |
| Genzyme Corporation | $19.40 | 2023 | |
| Idorsia Pharmaceuticals US INC | $18.57 | 2023 | Quviviq |
| Novartis Pharmaceuticals Corporation | $17.75 | 2020 | |
| Endo Pharmaceuticals INC. | $16.33 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $14.82 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.